Figure 2
From: APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury
Effect of APX-115 on insulin resistance and lipid profiles. (a) Insulin tolerance test after 12-week treatment with Nox inhibitors. (b) Plasma insulin level. (c) Homeostasis model assessment of insulin resistance (HOMA-IR) level. (d) Plasma lipid concentrations. (e) Tissue cholesterol concentrations. (f) Tissue triglyceride concentrations among groups. *P<0.05, **P<0.01, ***P<0.001 vs db/m groups, #P<0.05, ##P<0.01, ###P<0.001 vs db/db control.
